Connotation of Traditional Chinese Medicine in Treatment of Chronic Obstructive Pulmonary Disease by Regulating Gut Microbiota Based on "Lung and Large Intestine Being Interior-exterior Related"

WANG Hanxiao; LUAN Zheyu; FENG Jihong

doi:10.13422/j.cnki.syfjx.20231417

您当前的位置：

首页 >

文章列表页 >

Connotation of Traditional Chinese Medicine in Treatment of Chronic Obstructive Pulmonary Disease by Regulating Gut Microbiota Based on "Lung and Large Intestine Being Interior-exterior Related"

更新时间：2023-12-28

- Connotation of Traditional Chinese Medicine in Treatment of Chronic Obstructive Pulmonary Disease by Regulating Gut Microbiota Based on "Lung and Large Intestine Being Interior-exterior Related"
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 30, Issue 3, Pages: 169-177(2024)
- 作者机构：
  
  1.天津中医药大学，天津 301617
  2.天津中医药大学第二附属医院，天津 300250
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20231417
  CLC： R284;R285;R289;R287;R22;R2-031;R33;R24
- Published：05 February 2024，
  
  Published Online：02 November 2023，
  
  Received：25 August 2023，
- 稿件说明：
移动端阅览
王晗笑,栾哲宇,封继宏.基于“肺与大肠相表里”探讨中医药调控肠道菌群治疗慢性阻塞性肺疾病的内涵[J].中国实验方剂学杂志,2024,30(03):169-177.

WANG Hanxiao,LUAN Zheyu,FENG Jihong.Connotation of Traditional Chinese Medicine in Treatment of Chronic Obstructive Pulmonary Disease by Regulating Gut Microbiota Based on "Lung and Large Intestine Being Interior-exterior Related"[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(03):169-177.
王晗笑,栾哲宇,封继宏.基于“肺与大肠相表里”探讨中医药调控肠道菌群治疗慢性阻塞性肺疾病的内涵[J].中国实验方剂学杂志,2024,30(03):169-177. DOI： 10.13422/j.cnki.syfjx.20231417.

WANG Hanxiao,LUAN Zheyu,FENG Jihong.Connotation of Traditional Chinese Medicine in Treatment of Chronic Obstructive Pulmonary Disease by Regulating Gut Microbiota Based on "Lung and Large Intestine Being Interior-exterior Related"[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(03):169-177. DOI： 10.13422/j.cnki.syfjx.20231417.

摘要

慢性阻塞性肺疾病（COPD）是一种异质性肺部状态，其特征是持续性、并通常是进行性的气流阻塞，包括支气管炎、细支气管炎在内的气道异常及呼吸困难、咳嗽、咳痰在内的慢性呼吸道症状等，是世界范围内的主要死亡原因之一。中医学提出“肺与大肠相表里”，认为肺脏和大肠在生理病理方面相互联系影响，可采用补益肺脾肾，以及祛痰、逐瘀等治法肺肠同治。肠道菌群在人体的免疫、神经和代谢等方面发挥着重要作用，并可能通过影响肺肠组织结构功能，调节肺部炎症和免疫等作用于COPD。中医药能够调控肠道菌群使其恢复平衡，从而有利于COPD的恢复，如以补益肺补肾为主的治法能够调控肠道菌群，改善肺肠组织损伤，调节肺部免疫；以祛痰、逐瘀为主的治法能够调控肠道菌群，降低肺部炎症反应。该文基于“肺与大肠相表里”，以肠道菌群为关键点，阐述了中医药调控肠道菌群治疗COPD的内涵，旨在为临床通过肠道菌群治疗COPD提供新思路。

Abstract

Chronic obstructive pulmonary disease （COPD） is a heterogeneous lung condition characterized by persistent and often progressive airflow obstruction， including airway abnormalities （e.g.， bronchitis and bronchiolitis） and chronic respiratory symptoms （e.g.， dyspnea， cough， and expectoration）. It is one of the leading causes of death worldwide. According to the theory of traditional Chinese medicine （TCM）， the lung and large intestine are interior-exterior related. Therefore， COPD can be treated from both the lung and intestine by the methods of tonifying and invigorating lung， spleen， and kidney， dispelling phlegm， and expelling stasis. Gut microbiota plays a key role in human immunity， nerve， and metabolism and may act on COPD by affecting the structures and functions of lung and intestine tissue and regulating lung inflammation and immunity. TCM can restore the balance of gut microbiota， which is conducive to the recovery from COPD. For example， the treatment method of tonifying lung and invigorating kidney can regulate gut microbiota， alleviate pulmonary and intestinal injuries， and improve lung immunity. The treatment methods of dispelling phlegm and expelling stasis can regulate gut microbiota and reduce pulmonary inflammation. According to the TCM theory of lung and large intestine being interior-exterior related， this review elaborates on the connotation of TCM in the treatment of COPD by regulating gut microbiota， aiming to provide new ideas for the clinical treatment of COPD via gut microbiota.

关键词

慢性阻塞性肺病肠道菌群中医药肺与大肠相表里

Keywords

chronic obstructive pulmonary diseasegut microbiotatraditional Chinese medicinelung and large intestine being exterior-interior related

references

CELLI B，FABBRI L，CRINER G，et al.Definition and nomenclature of chronic obstructive pulmonary disease： Time for its revision［J］.Am J Respir Crit Care Med，2022，206（11）：1317-1325.

ZHU B，WANG Y，MING J，et al.Disease burden of COPD in China： A systematic review［J］.Int J Chron Obstruct Pulmon Dis，2018，13：1353-1364.

LOZANO R，NAGHAVI M，FOREMAN K，et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010：A systematic analysis for the Global Burden of Disease Study 2010［J］.Lancet，2012，380（9859）：2095-2128.

李正欢，张晓云，陈杨，等.2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读（一）——稳定期药物管理［J］.中国全科医学，2021，24（8）：923-929.

赵元辰.肺与大肠相表里的相关研究进展［J］.中国中西医结合外科杂志，2022，28（1）：142-144.

张艳，邵岩.“肺与大肠相表里”理论的研究进展［J］.医学理论与实践，2022，35（21）：3630-3632，3636.

ADAK A，KHAN M R.An insight into gut microbiota and its functionalities［J］.Cell Mol Life Sci，2019，76（3）：473-493.

GOMAA E Z.Human gut microbiota/microbiome in health and diseases：A review［J］.Antonie Van Leeuwenhoek，2020，113（12）：2019-2040.

PIEWNGAM P，DE METS F，OTTO M.Intestinal microbiota：The hidden gems in the gut？［J］.Asian Pac J Allergy Immunol，2020，38（4）：215-224.

QU L，CHENG Q，WANG Y，et al.COPD and gut-lung axis： How microbiota and host inflammasome influence COPD and related therapeutics［J］.Front Microbiol，2022，13：868086.

莫芳芳，马师雷，李鸿涛，等.基于中医古籍研究的“肺与大肠相表里”理论源流及其内涵探讨［J］.环球中医药，2015，8（2）：165-168.

胡宗仁.慢性阻塞性肺疾病稳定期的古代文献研究［D］.长沙：湖南中医药大学，2017.

柏正平，黄仁，胡学军，等.基于古代文献研究探讨慢性阻塞性肺疾病稳定期中医证型分布规律［J］.湖南中医杂志，2017，33（12）：124-125.

彭思敏，赵媚，许光兰，等.基于现代医案挖掘中医药治疗慢性阻塞性肺疾病的证治规律［J］.中国实验方剂学杂志，2022，28（15）：173-182.

JANDHYALA S M，TALUKDAR R，SUBRAMANYAM C，et al.Role of the normal gut microbiota［J］.World J Gastroenterol，2015，21（29）：8787-8803.

XIAO L，LIU Q，LUO M，et al.Gut microbiota-derived metabolites in irritable bowel syndrome［J］.Front Cell Infect Microbiol，2021，11：729346.

NI J，WU G D，ALBENBERG L，et al.Gut microbiota and IBD：Causation or correlation？［J］.Nat Rev Gastroenterol Hepatol，2017，14（10）：573-584.

ALBHAISI S，BAJAJ J S，SANYAL A J.Role of gut microbiota in liver disease［J］.Am J Physiol Gastrointest Liver Physiol，2020，318（1）：G84-G98.

FAN Y，PEDERSEN O.Gut microbiota in human metabolic health and disease［J］.Nat Rev Microbiol，2021，19（1）：55-71.

ZHANG Y，WANG Y，KE B，et al.TMAO：How gut microbiota contributes to heart failure［J］.Transl Res，2021，228：109-125.

BELVONCIKOVA P，MARONEK M，GARDLIK R.Gut dysbiosis and fecal microbiota transplantation in autoimmune diseases［J］.Int J Mol Sci，2022，23（18）：10729.

LU Y，YUAN X，WANG M，et al.Gut microbiota influence immunotherapy responses： Mechanisms and therapeutic strategies［J］.J Hematol Oncol，2022，15（1）：47.

CHANG L，WEI Y，HASHIMOTO K.Brain-gut-microbiota axis in depression：A historical overview and future directions［J］.Brain Res Bull，2022，182：44-56.

LI C X， LIU H Y， LIN X Y， et al.The gut microbiota and respiratory diseases：New evidence［J］.J Immunol Res，2020，2020：2340670.

HIEMSTRA P S，MCCRAY PBJR，BALS R.The innate immune function of airway epithelial cells in inflammatory lung disease［J］.Eur Respir J，2015，45（4）：1150-1162.

MARTIN C，BURGEL P R，LEPAGE P，et al.Host-microbe interactions in distal airways：Relevance to chronic airway diseases［J］.Eur Respir Rev，2015，24（135）：78-91.

WANG X，ZHANG J，WU Y，et al.SIgA in various pulmonary diseases［J］.Eur J Med Res，2023，28（1）：299.

MAO J，LI Y，BIAN Q，et al.The Bufei Jianpi formula improves mucosal immune function by remodeling gut microbiota through the SCFAs/GPR43/NLRP3 pathway in chronic obstructive pulmonary disease rats［J］.Int J Chron Obstruct Pulmon Dis，2022，17：1285-1298.

GRAYSON M H，CAMARDA L E，HUSSAIN S A，et al.Intestinal microbiota disruption reduces regulatory T cells and increases respiratory viral infection mortality through increased IFNγ production［J］.Front Immunol，2018，9：1587.

LAI H C，LIN T L，CHEN T W，et al.Gut microbiota modulates COPD pathogenesis： Role of anti-inflammatory parabacteroides goldsteinii lipopolysaccharide［J］.Gut，2022，71（2）：309-321.

RUTTEN E，LENAERTS K，BUURMAN W A，et al.Disturbed intestinal integrity in patients with COPD： Effects of activities of daily living［J］.Chest，2014，145（2）：245-252.

XIN X，DAI W，WU J，et al.Mechanism of intestinal mucosal barrier dysfunction in a rat model of chronic obstructive pulmonary disease：An observational study［J］.Exp Ther Med，2016，12（3）：1331-1336.

SCHOELER M，CAESAR R.Dietary lipids， gut microbiota and lipid metabolism［J］.Rev Endocr Metab Disord，2019，20（4）：461-472.

YANG L L，WEN M Y，LIU X H，et al.Feikang granules ameliorate pulmonary inflammation in the rat model of chronic obstructive pulmonary disease via TLR2/4-mediated NF-κB pathway［J］.BMC Complement Med Ther，2020，20（1）：170.

YOSHIDA N，EMOTO T，YAMASHITA T，et al.Bacteroides vulgatus and bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis［J］.Circulation，2018，138（22）：2486-2498.

RATAJCZAK W，RYŁ A，MIZERSKI A，et al.Immunomodulatory potential of gut microbiome-derived short-chain fatty acids （SCFAs）［J］.Acta Biochim Pol，2019，66（1）：1-12.

KOTLYAROV S.Role of short-chain fatty acids produced by gut microbiota in innate lung immunity and pathogenesis of the heterogeneous course of chronic obstructive pulmonary disease［J］.Int J Mol Sci，2022，23（9）：4768.

PARK J，KIM M，KANG S G，et al.Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway［J］.Mucosal Immunol，2015，8（1）：80-93.

JIANG M，LI Z，ZHANG F，et al.Butyrate inhibits iILC2-mediated lung inflammation via lung-gut axis in chronic obstructive pulmonary disease （COPD）［J］.BMC Pulm Med，2023，23（1）：163.

LE Y Q，WANG Y H，ZHOU L，et al.Cigarette smoke-induced HMGB1 translocation and release contribute to migration and NF-κB activation through inducing autophagy in lung macrophages［J］.J Cell Mol Med，2020，24（2）：1319-1331.

LI N，LIU X X，HONG M，et al.Sodium butyrate alleviates LPS-induced acute lung injury in mice via inhibiting HMGB1 release［J］.Int Immunopharmacol，2018，56：242-248.

KIM S，COVINGTON A，PAMER E G.The intestinal microbiota：Antibiotics，colonization resistance，and enteric pathogens［J］.Immunol Rev，2017，279（1）：90-105.

邹静，孙晓远，陈云霞，等.基于宏基因组学的慢性阻塞性肺疾病急性加重患者肠道菌群结构与功能相关性研究［J］.同济大学学报：医学版，2023，44（1）：41-51.

LI N，YI X，CHEN C，et al.The gut microbiome as a potential source of non-invasive biomarkers of chronic obstructive pulmonary disease［J］.Front Microbiol，2023，14：1173614.

LIU Y，TEO S M，MÉRIC G，et al.The gut microbiome is a significant risk factor for future chronic lung disease［J］.J Allergy Clin Immunol，2023，151（4）：943-952.

VASCONCELOS J A，MOTA A S，OLÍMPIO F，et al.Lactobacillus rhamnosus modulates lung inflammation and mitigates gut dysbiosis in a murine model of asthma-COPD overlap syndrome［J］.Probiotics Antimicrob Proteins，2023

HUANG W，YAU Y，ZHU J，et al.Effect of electroacupuncture at Zusanli （ST36） on intestinal microbiota in rats with chronic atrophic gastritis［J］.Front Genet，2022，13：824739.

HAN Q Q，FU Y，LE J M，et al.Electroacupuncture may alleviate behavioral defects via modulation of gut microbiota in a mouse model of Parkinson's disease［J］.Acupunct Med，2021，39（5）：501-511.

BAI H，GU R J，CHEN L Y，et al.Electroacupuncture interventions alleviates myocardial ischemia reperfusion injury through regulating gut microbiota in rats［J］.Microvasc Res，2021，138：104235.

ZHANG X F，XIANG S Y，GENG W Y，et al.Electro-acupuncture regulates the cholinergic anti-inflammatory pathway in a rat model of chronic obstructive pulmonary disease［J］.J Integr Med，2018，16（6）：418-426.

WANG J，REN C，JIN L，et al.Seabuckthorn Wuwei Pulvis attenuates chronic obstructive pulmonary disease in rat through gut microbiota-short chain fatty acids axis［J］.J Ethnopharmacol，2023，314：116591.

沈俊希，朱星，陈云志，等.补肺汤对慢性阻塞性肺疾病肺气虚证大鼠肺-肠轴的影响［J］.中国实验方剂学杂志，2023，29（7）：47-56.

JIAO J，TANG Q，WANG T J，et al.The therapeutic effect of Xuanbai Chengqi decoction on chronic obstructive pulmonary disease with excessive heat in the lung and fu-organs based on gut and lung microbiota as well as metabolic profiles［J］.J Chromatogr B Analyt Technol Biomed Life Sci，2022，1198：123250.

薛佳茜.基于“肺与大肠相表里”研究清源化痰颗粒对慢阻肺急性加重期炎症反应及肠道菌群的影响［D］.南京：南京中医药大学，2021.

蔡华珠，洪菲萍，纪立金，等.“正气存内，邪不可干”的内涵及运用探析［J］.中华中医药杂志，2015，30（4）：987-989.

窦增娥，姚惠青，赵永祥，等.基于“肺与大肠相表里”复方苍术方治疗慢性阻塞性肺疾病［J］.世界中医药，2021，16（1）：137-141.

闫玉琴，贾琦，张山，等.基于肺-肠轴理论的益气通腑灌肠法治疗老年AECOPD临床观察［J］.北京中医药，2021，40（12）：1375-1378.

周罗川.虫草素与虫草多糖调节肠道菌群缓解COPD炎症的实验研究［D］.昆明：云南中医药大学，2021.

韩思思.益气涤痰破瘀方干预肺-肠微生态平衡防治COPD的实验研究［D］.昆明：云南中医药大学，2020.

WANG Y，LI N，LI Q，et al.Xuanbai Chengqi decoction ameliorates pulmonary inflammation via reshaping gut microbiota and rectifying Th17/Treg imbalance in a murine model of chronic obstructive pulmonary disease［J］.Int J Chron Obstruct Pulmon Dis，2021，16：3317-3335.

刘海叶，贾智玲，董文军，等.基于16S rDNA测序技术探讨慢性阻塞性肺疾病大鼠肠道菌群变化及玉屏风颗粒的防治作用机制［J］.中华中医药杂志，2022，37（12）：7328-7333.

JIA Y，HE T，WU D，et al.The treatment of Qibai Pingfei capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota［J］.J Transl Med，2022，20（1）：281.

骆亚莉，周啸天，魏本君，等.中医学对炎性微环境与炎症恶性转化的认识［J］.时珍国医国药，2022，33（8）：1966-1968.

孔艳华，史琦，阎玥，等.理肺汤对慢性阻塞性肺疾病大鼠肠道菌群和炎性因子的影响［J］.中华中医药杂志，2017，32（1）：341-343.

严明月，杨震，刘汶睿，等.理肺汤治疗慢性阻塞性肺疾病的临床疗效及对患者肠道菌群和炎症因子的影响［J］.吉林中医药，2023，43（5）：551-555.

陈小丽.基于“肺与大肠相表里”通过研究肠道菌群变化分析清金化痰汤治疗AECOPD的疗效机制［D］.南宁：广西中医药大学，2021.

YONG W，ZHANG L，CHEN Y，et al.Jianpi Huatan Tongfu granule alleviates inflammation and improves intestinal flora in patients with acute exacerbation of chronic obstructive pulmonary disease［J］.J Int Med Res，2020，48（4）：300060520909235.

张露.基于“肺与大肠相表里”理论观察车前子粗多糖胶囊干预老年COPD稳定期的临床研究［D］.兰州：甘肃中医药大学，2020.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Traditional Chinese Medicine in Regulating Gut Microbiota in Treating Metabolic-associated Fatty Liver Disease

Role of Mitophagy in Prevention and Treatment of Heart Failure Based on PINK1/Parkin Pathway and Treatment with Traditional Chinese Medicine： A Review

Analysis of Molecular Mechanism of Angong Niuhuangwan in Alleviating Traumatic Brain Injury Based on Single Cell Sequencing

Related Author

TANG Yinpei

ZHU Zhengwang

WANG Bing

ZHU Pingsheng

XU Qian

WANG Wenting

LI Yiwen

CUI Jing

Related Institution

Henan University of Chinese Medicine

The Sixth People's Hospital of Shanghai Jiao Tong University

National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine， Xiyuan Hospital of China Academy of Chinese Medical Sciences

Experimental Research Center， China Academy of Chinese Medical Sciences

Liaoning University of Traditional Chinese Medicine（TCM）

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰